Summary
The PD-1 inhibitors market is led by Merck’s KEYTRUDA and Bristol Myers Squibb’s OPDIVO, which together still dominate global revenue and remain the standard-bearers in the category.
Challenger PD-1 drugs such as Sanofi/Regeneron’s LIBTAYO, GSK’s JEMPERLI, and Incyte’s ZYNYZ have carved out positions in specific cancers rather than trying to beat the leaders head-to-head across every indication.
China-origin PD-1 inhibitors, including BeOne’s TEVIMBRA, Coherus BioSciences/Junshi Biosciences’ LOQTORZI, Jiangsu Hengrui Medicine’s AIRUIKA, Henlius’ HANSIZHUANG, and Innovent Biologics/Eli Lilly’s TYVYT, are reshaping competition through lower pricing, mu...
